Novartis (nvs) Stock Research
Last Updated by Anonymous | Update This Page Now
Company Description: Novartis AG provides is a global healthcare solutions provider that develops, manufactures, distributes, and sells therapeutic pharmaceuticals, vaccines, diagnostic services, over the counter medicines, veterinary products and medicinal supplies, and ophthalmic products. Update
Health Care Industry Research & Analysis: The health care industry depends on the care of health-related services by professionals for the benefit of patients. Medical device markers, insurance companies, pharmaceutical drug developers and government institutions are major participants in the treatment of sick, injured and disabled patients. Health Care Trading Strategy: Health Care stocks tend to be less sensitive to economic changes. Look for undervalued health care investments at any point in the business cycle when stock prices are low. However, biotech, employment staffing and insurance companies may all decrease during recessions for different reasons. Government intervention is another important factor in health care investments, since government spending in health care is a very large portion of overall health care spending. When governments change spending plans, different sub-sectors in the industry are significantly affected. Upward sloping stock charts and financial news may indicate a selling opportunity while the opposite means that stocks are becoming undervalued.
Industry Sub Sector: . Novartis is a dominant industry leader due to its personnel, experience and financial strengths. Industry leaders are difficult to compete against, which decreases business and investor risks.
Market Challenges: Opportunities: Solutions:
Novartis possesses significant barriers to entry that slows competitive threats and increases profits.
Strategy: Novartis has a narrow focus that serves a particular customer niche with either a unique product or with a low cost advantage over competitors. (read more). Competitive Advantages:
Current Revenue Sources: Future Revenue Sources: